SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4

Disclosure: J. Blair: Advisory Board Member; Self; Novo Nordisk. Speaker; Self; Novo Nordisk, Ipsen. Other; Self; Novo Nordisk. B.S. Miller: Consulting Fee; Self; Abbvie, Bristol-Myers Squibb, Novo Nordisk, Pfizer, Inc., EMD Serono, Endo Pharmaceuticals. Grant Recipient; Self; Alexion Pharmaceutical...

Descripción completa

Detalles Bibliográficos
Autores principales: Blair, Joanne, Miller, Bradley Scott, Hojby, Michael, Maniatis, Aristides K, Mori, Jun, Boettcher, Volker, Kim, Ho-Seong, Bang, Rikke Beck, Fries Jensen, Lasse De, Polak, Michel, Horikawa, Reiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Endocrine Disrupting Chemicals
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554129/
http://dx.doi.org/10.1210/jendso/bvad114.1082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554129/
http://dx.doi.org/10.1210/jendso/bvad114.1082

Ejemplares similares